Expansion of NEUROD2 phenotypes to include developmental delay without seizures.
Emily K MisAnnalisa G SegaRebecca H SignerTracy CartwrightWeizhen JiJulian A MartinezStanley F NelsonChristina G S PalmerHane LeeThomas MitzelfeltMonica Konstantinonull nullLauren JeffriesMustafa K KhokhaElysa MarcoMartin G MartinSaquib Ali LakhaniPublished in: American journal of medical genetics. Part A (2021)
De novo heterozygous variants in the brain-specific transcription factor Neuronal Differentiation Factor 2 (NEUROD2) have been recently associated with early-onset epileptic encephalopathy and developmental delay. Here, we report an adolescent with developmental delay without seizures who was found to have a novel de novo heterozygous NEUROD2 missense variant, p.(Leu163Pro). Functional testing using an in vivo assay of neuronal differentiation in Xenopus laevis tadpoles demonstrated that the patient variant of NEUROD2 displays minimal protein activity, strongly suggesting a loss of function effect. In contrast, a second rare NEUROD2 variant, p.(Ala235Thr), identified in an adolescent with developmental delay but lacking parental studies for inheritance, showed normal in vivo NEUROD2 activity. We thus provide clinical, genetic, and functional evidence that NEUROD2 variants can lead to developmental delay without accompanying early-onset seizures, and demonstrate how functional testing can complement genetic data when determining variant pathogenicity.
Keyphrases
- early onset
- late onset
- copy number
- transcription factor
- young adults
- mitochondrial dna
- mental health
- genome wide
- magnetic resonance
- magnetic resonance imaging
- electronic health record
- case report
- gene expression
- escherichia coli
- computed tomography
- small molecule
- staphylococcus aureus
- multiple sclerosis
- intellectual disability
- temporal lobe epilepsy
- white matter
- childhood cancer
- contrast enhanced